Regeneus Ltd. (AU:CMB) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cambium Bio Limited has successfully raised A$3.0 million in a capital round involving strategic and existing investors, including AventaCell Biomedical Corp and Zheng Yang Biomedical Technology. This funding will support the advancement of Cambium’s lead product, Elate Ocular®, into Phase 3 clinical trials for dry eye disease. The investment also highlights strong confidence in Cambium’s innovative biologics and its growth potential in the regenerative medicine field.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.